Kristi Rosa

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

The SKYSCRAPER-05 trial shed light on the use of perioperative tiragolumab plus atezolizumab with or without chemotherapy in NSCLC.

Ifinatamab deruxtecan was efficacious and had a manageable safety profile in patients with previously treated extensive-stage small cell lung cancer.

Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

Perioperative nivolumab maintained HRQOL and decreased the risk of deterioration vs placebo in patients with stage III N2 NSCLC.

COMPEL data support osimertinib plus chemotherapy in EGFR-mutated NSCLC after non-CNS progression on frontline osimertinib.

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Tisotumab vedotin is cleared in Hong Kong for the treatment of select patients with cervical cancer.

Trastuzumab deruxtecan has been approved in Japan for patients with HR+, HER2-low or -ultralow metastatic breast cancer.

The BRF14 study, which examined imatinib in patients with gastrointestinal stromal tumors, has the longest follow-up time in this sarcoma.

JAVELIN Bladder Medley data show PFS improvement with avelumab plus sacituzumab govitecan as first-line maintenance vs avelumab alone in urothelial cancer.

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.

Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.

A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.

TACE plus atezolizumab and bevacizumab may represent effective option for untreated intermediate-to-high tumor burden unresectable HCC.

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Givastomig paired with chemoimmunotherapy was tolerable and elicited responses in CLDN18.2+ gastric, esophageal, and GEJ cancers.

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy) for locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for use in patients with relapsed/refractory multiple myeloma.

Data from the first stage of a phase 2a study suggest that tigilanol tiglate reduced tumor volume in patients with soft tissue sarcoma.

Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.